Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group of tumors with
complicated treatment options that depend on pathological grading, clinical staging, and …

Through diagnostic imaging and peptide receptor radionuclide therapy, nuclear medicine
has earned a major role in gastroenteropancreatic neuroendocrine tumors (GEP NETs) …

Purpose: Immune checkpoint blockade has improved outcomes across tumor types; little is
known about the efficacy of these agents in rare tumors. We report the results of the …

Purpose: The purpose of this study is to develop and validate a nomogram model combing
radiomics features and clinical characteristics to preoperatively differentiate grade 1 and …

The diagnosis and management of pancreatic neuroendocrine neoplasms (NENs) have
evolved significantly in recent years. There are several diagnostic and therapeutic …

There is no consensus on optimal follow-up for completely resected gastroenteropancreatic
neuroendocrine tumors. Published guidelines for follow-up are complex and emphasize …

Introduction: Recent advances in diagnostic modalities and therapeutic agents have raised
the importance of prognostic factors in predicting overall survival, as well as predictive …

Introduction: Since the initial approval of everolimus in 2011, there have been a number of
important changes in therapeutic/diagnostic modalities as well as classification/staging …

Objectives Except pancreatic adenocarcinoma, pancreatic cancer has several uncommon
histological subtypes, including invasive intraductal papillary mucinous neoplasm (IPMN) …

ABSTRACT 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is now
approved for patients with advanced gastroenteropancreatic neuroendocrine tumors (NET) …